Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06994806 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

A Phase 1 study of Solid Tumor Malignancies, sponsored by Kumquat Biosciences.

Recruiting
Registry status
Phase 1
Development phase
84
Enrollment target
15
Study locations

NCT06994806 is a Phase 1 study of Solid Tumor Malignancies that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 84 participants, below the 188-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (55% lower). The trial reports 15 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06994806, a Phase 1 study of Solid Tumor Malignancies, is actively recruiting participants, sponsored by Kumquat Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
84 participants
Enrollment target
15
Study locations

Study Summary

The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * What is the safe dose of KQB168 by itself or in combination with pembrolizumab? * Does KQB168 alone or in combination with pembrolizumab decrease the size of the tumor? * What happens to KQB168 in the body? Participants will: * Take KQB168 daily, alone or in combination with pembrolizumab * Visit the clinic about 8 times in the first 8 weeks, and then once every 3 weeks after that

Conditions Studied

Solid Tumor Malignancies

Interventions

  • DRUG Pembrolizumab
  • DRUG KQB168

Study Locations (15)

Texas

  • NEXT Austin - Austin
  • Mary Crowley Cancer Research Centers - Dallas
  • UT MD Anderson Cancer Center - Houston - Houston
  • NEXT Huston - Houston
  • NEXT Oncology - San Antonio

Florida

  • Mayo Clinic - Jacksonville - Jacksonville
  • Florida Cancer Specialists - Sarasota - Sarasota

Arizona

  • Mayo Clinic - Phoenix - Phoenix

California

  • USC Norris Comprehensive Cancer Center - Los Angeles

Colorado

  • Sarah Cannon Cancer Institute at HealthONE - Denver

Connecticut

  • Yale Cancer Center- New Haven - New Haven

Iowa

  • University of Iowa - Iowa City

Minnesota

  • Mayo Clinic - Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2025-06-24
Est. Completion 2028-05-31
Phase Phase 1

Sponsor

Kumquat Biosciences

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06994806

The ClinicalTrials.gov registry entry for NCT06994806 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (55% lower). The listed sponsor is Kumquat Biosciences, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06994806 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Texas, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06994806 about?

NCT06994806 is a clinical study titled "A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies". The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * What is the safe dose of KQB168 by itself or in combination with pembrolizumab? * Does KQB168 alone ...

What is the current status of trial NCT06994806?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2025-06-24. Estimated completion is 2028-05-31.

What conditions does trial NCT06994806 study?

This clinical trial studies the following conditions: Solid Tumor Malignancies.

What interventions are being tested in trial NCT06994806?

The interventions under investigation include: Pembrolizumab (DRUG), KQB168 (DRUG).

Who is sponsoring clinical trial NCT06994806?

This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06994806 being conducted?

This trial has 15 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor Malignancies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor Malignancies

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.